Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia

Waldenstrom’s macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma with indolent course and prolonged disease course. The first-in-class Bruton’s tyrosine kinase inhibitor, ibrutinib, has shown significant activity and a distinct adverse event profile among both newly diagnosed and relapsed/r...

Descripción completa

Detalles Bibliográficos
Autores principales: Papanota, Aristea-Maria, Ntanasis-Stathopoulos, Ioannis, Kastritis, Efstathios, Dimopoulos, Meletios A, Gavriatopoulou, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717707/
https://www.ncbi.nlm.nih.gov/pubmed/31695539
http://dx.doi.org/10.2147/JBM.S183997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717707/
https://www.ncbi.nlm.nih.gov/pubmed/31695539
http://dx.doi.org/10.2147/JBM.S183997

Ejemplares similares